EMA says AstraZeneca/Oxford COVID-19 jab may not be fit for January OK

 

• AstraZeneca (NASDAQ:AZN) and the University of Oxford's COVID-19 vaccine might not be approved in January, said Noel Wathion, Deputy Executive Director of the European Medicines Authority (EMA), according to Reuters.
• “They have not even filed an application with us yet”, Wathion said in an interview with Belgian newspaper Het Nieuwsblad.
• European regulators have only received some information about the vaccine, Wathion said.
• “Not even enough to warrant a conditional marketing licence”, he said. “We need additional data about the quality of the vaccine. And after that, the company has to formally apply.”
• This made it “improbable” that an approval could already be granted next month, Wathion said.
• Related names: Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Johnson & Johnson (NYSE:JNJ), Novavax (NASDAQ:NVAX)
• Yesterday, the Serum Institute of India said that the British and Indian governments expects to approve the Oxford/AstraZeneca shot for emergency use within a few days.
• https://seekingalpha.com/news/3647663-ema-says-astrazeneca-oxford-covidminus-19-jab-unfit-for-january-approval